SEC Form 4
Neurocrine Biosciences Inc (NBIX) insider trading
In the 12 months to Nov 5, 2026, 15 NBIX insiders reported open-market sales of $80.2M across 26 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $80.2M
- 26 filings · 15 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 26 of 26
- All $80.2M sold was pre-arranged
Who traded NBIX, and when
- Sale
- Sale, pre-arranged (10b5-1)
NBIX daily close from Nov 5, 2025 to Nov 5, 2026, between $123.10 and $185.50, last $163.09. 26 sale and 0 purchase filings by 15 insiders, marked at their filing dates. Kevin Charles Gorman, Director: sold $37.8M across 1 filing, first filed May 21, 2026, last May 21, 2026. Julie Cooke, Chief Human Resources Officer: sold $5.8M across 1 filing, first filed Jun 4, 2026, last Jun 4, 2026. Kyle Gano, Chief Executive Officer: sold $4.8M across 1 filing, first filed Jan 20, 2026, last Jan 20, 2026. George J. Morrow, Director: sold $4.5M across 2 filings, first filed Nov 26, 2025, last Nov 3, 2026. Darin Lippoldt, Chief Legal Officer: sold $4.2M across 3 filings, first filed Dec 10, 2025, last Jul 13, 2026. Stephen A. Sherwin, Director: sold $4.1M across 1 filing, first filed Jun 9, 2026, last Jun 9, 2026. 9 others: sold $18.9M across 17 filings, first filed Nov 6, 2025, last Sep 15, 2026.
Largest mark · tap a row for others
Kevin Charles Gorman · Director
Sale $37,824,872
245,088 shares at $154.33 avg
Filed May 21, 2026 · traded May 19
Pre-arranged (10b5-1) · close on filing date $155.50
Kevin Charles Gorman · Director
Director
$37.8M soldJulie Cooke · Chief Human Resources Officer
Chief Human Resources Officer
$5.8M soldKyle Gano · Chief Executive Officer
Chief Executive Officer
$4.8M soldGeorge J. Morrow · Director
Director
$4.5M soldDarin Lippoldt · Chief Legal Officer
Chief Legal Officer
$4.2M soldStephen A. Sherwin · Director
Director
$4.1M sold9 others
Combined, one mark per week
$18.9M soldOpen-market trades
26 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Kevin Charles Gorman | Director | $37.8M | — | 1 | 100% of sales | |
| Julie Cooke | Chief Human Resources Officer | $5.8M | — | 1 | 100% of sales | |
| Kyle Gano | Chief Executive Officer | $4.8M | — | 1 | 100% of sales | |
| George J. Morrow | Director | $4.5M | — | 2 | 100% of sales | |
| Darin Lippoldt | Chief Legal Officer | $4.2M | — | 3 | 100% of sales | |
| Stephen A. Sherwin | Director | $4.1M | — | 1 | 100% of sales | |
| Ingrid Delaet | Chief Regulatory Officer | $3.7M | — | 3 | 100% of sales | |
| Jude Onyia | Chief Scientific Officer | $3.5M | — | 2 | 100% of sales | |
| William H. Rastetter | Director | $2.7M | — | 1 | 100% of sales | |
| Richard F. Pops | Director | $2.4M | — | 1 | 100% of sales | |
| Gary A. Lyons | Director | $2.3M | — | 1 | 100% of sales | |
| Leslie V. Norwalk | Director | $2.0M | — | 4 | 100% of sales | |
| Eric Benevich | Chief Commercial Officer | $1.2M | — | 2 | 100% of sales | |
| David W. Boyer | Chief Corp. Affairs Officer | $739.1K | — | 2 | 100% of sales | |
| Matt Abernethy | Chief Financial Officer | $363.3K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | George J. Morrow Director | SalePre-arranged (10b5-1) | 15,000 | $155.73 | $2.3M | 15,560 | |
traded | Matt Abernethy Chief Financial Officer | SalePre-arranged (10b5-1) | 2,311 | $157.20 | $363.3K | 42,808 | |
traded | David W. Boyer Chief Corp. Affairs Officer | SalePre-arranged (10b5-1) | 826 | $157.45 | $130.1K | 8,722 | |
traded | Eric Benevich Chief Commercial Officer | SalePre-arranged (10b5-1) | 2,154 | $154.61 | $333.0K | 64,408 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 1,250 | $182.01 | $227.5K | 1,588 | |
traded | Darin Lippoldt Chief Legal Officer | SalePre-arranged (10b5-1) | 10,000 | $179.60 | $1.8M | 54,729 | |
traded | Ingrid Delaet Chief Regulatory Officer | SalePre-arranged (10b5-1) | 4,367 | $181.02 | $790.5K | 16,225 | |
traded | Ingrid Delaet Chief Regulatory Officer | SalePre-arranged (10b5-1) | 14,571 | $178.65 | $2.6M | 16,225 | |
traded | Darin Lippoldt Chief Legal Officer | SalePre-arranged (10b5-1) | 10,000 | $170.15 | $1.7M | 54,729 | |
traded | Stephen A. Sherwin Director | SalePre-arranged (10b5-1) | 25,000 | $165.32 | $4.1M | 23,532 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 1,250 | $168.06 | $210.1K | 2,838 | |
traded | Julie Cooke Chief Human Resources Officer | SalePre-arranged (10b5-1) | 36,937 | $156.22 | $5.8M | 39,631 | |
traded | Jude Onyia Chief Scientific Officer | SalePre-arranged (10b5-1) | 11,000 | $160.25 | $1.8M | 25,846 | |
traded | Ingrid Delaet Chief Regulatory Officer | SalePre-arranged (10b5-1) | 2,261 | $156.71 | $354.3K | 16,225 | |
traded | Jude Onyia Chief Scientific Officer | SalePre-arranged (10b5-1) | 11,000 | $155.53 | $1.7M | 25,846 | |
traded | David W. Boyer Chief Corp. Affairs Officer | SalePre-arranged (10b5-1) | 3,888 | $156.64 | $609.0K | 7,799 | |
traded | Kevin Charles Gorman Director | SalePre-arranged (10b5-1) | 245,088 | $154.33 | $37.8M | 511,293 | |
traded | Richard F. Pops Director | SalePre-arranged (10b5-1) | 15,000 | $157.65 | $2.4M | 34,480 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 3,810 | $155.01 | $590.6K | 2,429 | |
traded | Kyle Gano Chief Executive Officer | SalePre-arranged (10b5-1) | 36,400 | $132.70 | $4.8M | 140,407 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 6,190 | $152.78 | $945.7K | 6,239 | |
traded | Darin Lippoldt Chief Legal Officer | SalePre-arranged (10b5-1) | 4,376 | $159.65 | $698.6K | 43,405 | |
traded | Gary A. Lyons Director | SalePre-arranged (10b5-1) | 15,000 | $152.61 | $2.3M | 120,482 | |
traded | Eric Benevich Chief Commercial Officer | SalePre-arranged (10b5-1) | 5,970 | $151.74 | $905.9K | 44,893 | |
traded | George J. Morrow Director | SalePre-arranged (10b5-1) | 15,000 | $143.37 | $2.2M | 7,068 | |
traded | William H. Rastetter Director | SalePre-arranged (10b5-1) | 18,000 | $151.82 | $2.7M | 40,360 |
GET /stocks/filings/vX/form-4?tickers=NBIX&filing_date.gte=2025-11-05&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NBIX"
],
"issuer_cik": "0000914475",
"owner_cik": "0001068754",
"accession_number": "0001068754-26-000009",
"form_type": "4",
"filing_date": "2026-11-03",
"period_of_report": "2026-10-30",
"issuer_name": "NEUROCRINE BIOSCIENCES INC",
"issuer_trading_symbol": "NBIX",
"owner_name": "MORROW GEORGE J",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1466,
"transaction_price_per_share": 166.7748,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 13186,
"transaction_value": 244491.8568,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."
},
{
"id": "F8",
"description": "Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $166.26 to $167.20. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."
}
]
},
{
"tickers": [
"NBIX"
],
"issuer_cik": "0000914475",
"owner_cik": "0001068754",
"accession_number": "0001068754-26-000009",
"form_type": "4",
"filing_date": "2026-11-03",
"period_of_report": "2026-10-30",
"issuer_name": "NEUROCRINE BIOSCIENCES INC",
"issuer_trading_symbol": "NBIX",
"owner_name": "MORROW GEORGE J",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 600,
"transaction_price_per_share": 163.7083,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 16786,
"transaction_value": 98224.98000000001,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The dispositions reported in this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Additionally,\nIssuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."
},
{
"id": "F5",
"description": "Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.21 to $164.01. The Reporting Person has provided to the issuer, and\nwill provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 162 records
- Option exercises78 records
- Tax withholding58 records
- Grants and awards20 records
- Gifts6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Neurocrine Biosciences Inc's CEO sold stock?
Yes. Kyle Gano (CEO) sold 36,400 shares ($4.8M) in Jan 2026, all under a pre-arranged 10b5-1 plan.
How current is NBIX’s insider data?
These are NBIX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track NBIX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NBIX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.